Is Urate-lowering therapy a prevention of first gout episode?
DOI:
https://doi.org/10.12775/QS.2025.43.61492Keywords
urate-lowering therapy, gout, symptomless hyperuricemia, serum uric acidAbstract
The growing problem of gout is beginning to raise questions about how we can effectively prevent this disease. This work examines the effect of urate-lowering therapy on preventing the onset of a first episode of gout—an effect that is not entirely clear, despite the fact that such therapy is an essential tool for controlling gout flares. A growing database allows us to analyze the impact of hyperuricemia, which has so far been presumed to be a major contributor to the development of gout, and assess its actual impact on the development of the disease.
References
1. Danve A, Sehra ST, Neogi T. Role of diet in hyperuricemia and gout. Best Practice and Research: Clinical Rheumatology 35 2021.
2. Roddy E, Doherty M. Epidemiology of gout. Arthritis Research and Therapy 12 2010.
3. Ankli B. Gicht – Neues zur epidemiologie. Therapeutische Umschau 73 2016 125–129.
4. Mertz DP. Changes in the epidemiology, symptomatology and prognosis of gout. Versicherungsmedizin / herausgegeben von Verband der Lebensversicherungs-Unternehmen e.V. und Verband der Privaten Krankenversicherung e.V 44 1992 10–13.
5. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology 16 2020 380–390.
6. Szczeklik A. Interna Szczeklika. Medycyna Praktyczna, 2024.
7. Du L, Zong Y, Li H et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy 9 2024.
8. Boocock J, Leask M, Okada Y et al. Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control. Hum Mol Genet 2020; 29: 923–943.
9. Kuwabara M, Niwa K, Hisatome I et al. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases Five-Year Japanese Cohort Study. Hypertension 2017; 69: 1036–1044.
10. Liu YF, Han L, Geng YH, Wang HH, Yan JH, Tu SH. Nonlinearity association between hyperuricemia and all-cause mortality in patients with chronic kidney disease. Sci Rep 2024; 14.
11. Nadeem ZA, Nashwan AJ. Comment on: ‘Gout/hyperuricemia reduces the risk of Alzheimer’s disease: A meta-analysis based on latest evidence’. Brain and Behavior 14 2024.
12. Zhou X, Matavelli L, Frohlich ED. Uric acid: Its relationship to renal hemodynamics and the renal renin-angiotensin system. Curr Hypertens Rep 2006; 8: 120–124.
13. Park JH, Jin YM, Hwang S, Cho DH, Kang DH, Jo I. Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: A mechanism for uric acid-induced cardiovascular disease development. Nitric Oxide 2013; 32: 36–42.
14. Wan X, Xu C, Lin Y et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol 2016; 64: 925–932.
15. Lu Z, Lu F, Zhang R, Guo S. Interaction between anemia and hyperuricemia in the risk of all-cause mortality in patients with chronic kidney disease. Front Endocrinol (Lausanne) 2024; 15.
16. Crane JK, Mongiardo KM. Pro-inflammatory effects of uric acid in the gastrointestinal tract. Immunol Invest 2014; 43: 255–266.
17. Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA. Uric Acid and Oxidative Stress—Relationship with Cardiovascular, Metabolic, and Renal Impairment. International Journal of Molecular Sciences 23 2022.
18. Weaver VM, Schwartz BS, Jaar BG et al. Associations of uric acid with polymorphisms in the δ-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers. Environ Health Perspect 2005; 113: 1509–1515.
19. Álvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology 49 2010 2010–2015.
20. Brzozowski T. Konturek : Fizjologia człowieka. 2019.
21. MCCARTY DJ, HOLLANDER JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54: 452–460.
22. Chhana A, Pool B, Wei Y et al. Human Cartilage Homogenates Influence the Crystallization of Monosodium Urate and Inflammatory Response to Monosodium Urate Crystals: A Potential Link Between Osteoarthritis and Gout. Arthritis and Rheumatology 2019; 71: 2090–2099.
23. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology 16 2020 380–390.
24. Chih MH, Lee HL, Lee T. The culprit of gout: triggering factors and formation of monosodium urate monohydrate. CrystEngComm 2015; 18: 290–297.
25. Kirilmaz B, Asgun F, Alioglu E et al. High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens 2010; 12: 136–144.
26. Riaz M, Kury LT Al, Atzaz N et al. Carvacrol Alleviates Hyperuricemia-Induced Oxidative Stress and Inflammation by Modulating the NLRP3/NF-κB Pathwayt. Drug Des Devel Ther 2022; 16: 1159–1170.
27. Kim SM, Lee SH, Kim YG et al. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am J Physiol Renal Physiol 2015; 308: F993–F1003.
28. Alberts BM, Bruce C, Basnayake K, Ghezzi P, Davies KA, Mullen LM. Secretion of IL-1β from monocytes in gout is redox independent. Front Immunol 2019; 10.
29. Li S, Cui L, Cheng J et al. Repeated measurements of serum urate and mortality: A prospective cohort study of 152,358 individuals over 8 years of follow-up. Arthritis Res Ther 2020; 22.
30. Zhang Q, Gong H, Lin C et al. The prevalence of gout and hyperuricemia in middle-aged and elderly people in Tibet Autonomous Region, China: A preliminary study. Medicine (United States) 2020; 99.
31. Cabău G, Crișan TO, Klück V, Popp RA, Joosten LAB. Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia. Immunological Reviews 294 2020 92–105.
32. Juraschek SP, Yokose C, McCormick N, Miller ER, Appel LJ, Choi HK. Effects of Dietary Patterns on Serum Urate: Results From a Randomized Trial of the Effects of Diet on Hypertension. Arthritis and Rheumatology 2021; 73: 1014–1020.
33. FitzGerald JD, Dalbeth N, Mikuls T et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) 2020; 72: 744–760.
34. Hidalgo-Mora JJ, García-Vigara A, Sánchez-Sánchez ML, García-Pérez MÁ, Tarín J, Cano A. The Mediterranean diet: A historical perspective on food for health. Maturitas 132 2020 65–69.
35. Yokose C, McCormick N, Rai SK et al. Effects of low-fat, mediterranean, or low-carbohydrate weight loss diets on serum urate and cardiometabolic risk factors: A secondary analysis of the dietary intervention randomized controlled trial (direct). Diabetes Care 2020; 43: 2812–2820.
36. Guasch-Ferré M, Bulló M, Babio N et al. Mediterranean diet and risk of hyperuricemia in elderly participants at high cardiovascular risk. Journals of Gerontology - Series A Biological Sciences and Medical Sciences 2013; 68: 1263–1270.
37. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men. New England Journal of Medicine 2004; 350: 1093–1103.
38. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136–3141.
39. Zhang Y, Chen C, Choi H et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012; 71: 1448–1453.
40. Choi HK, McCormick N, Lu N, Rai SK, Yokose C, Zhang Y. Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia. Arthritis and Rheumatology 2020; 72: 157–165.
41. Glynn RJ, Campion EW, Silbert JE. Trends in serum uric acid levels. Arthritis Rheum 1983; 26: 87–93.
42. Maglio C, Peltonen M, Neovius M et al. Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: A non-randomised, prospective, controlled intervention trial. Ann Rheum Dis 2017; 76: 688–693.
43. Yeo C, Kaushal S, Lim B et al. Impact of bariatric surgery on serum uric acid levels and the incidence of gout—A meta-analysis. Obesity Reviews 2019; 20: 1759–1770.
44. Lu J, Bai Z, Chen Y et al. Effects of bariatric surgery on serum uric acid in people with obesity with or without hyperuricaemia and gout: a retrospective analysis. Rheumatology (United Kingdom) 2021; 60: 3628–3634.
45. Romero-Talamás H, Daigle CR, Aminian A, Corcelles R, Brethauer SA, Schauer PR. The effect of bariatric surgery on gout: A comparative study. Surgery for Obesity and Related Diseases 2014; 10: 1161–1165.
46. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Care and Research 51 2004 1023–1029.
47. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: A prospective study. Lancet 2004; 363: 1277–1281.
48. Ralston SH, Capell HA, Sturrock RD. Alcohol and response to treatment of gout. Br Med J (Clin Res Ed) 1988; 296: 1641–1642.
49. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases 76 2017 29–42.
50. Tai CJ, Wu CC, Lee KT et al. The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights From a Population-Based, Propensity Score-Matched Analysis. Clin Pharmacol Ther 2022; 111: 655–663.
51. Luo Y, Song Q, Li J et al. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis. BMC Nephrol 2024; 25.
52. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiology in Review 19 2011 265–271.
53. Richette P. Allopurinol and risk of myocardial infarction. Heart 101 2015 659–660.
54. Mellin V, Isabelle M, Oudot A et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005; 26: 1544–1550.
55. Qazi SU, Qamar U, Maqsood MT et al. Efficacy of Allopurinol in Improving Endothelial Dysfunction: A Systematic Review and Meta-Analysis. High Blood Pressure and Cardiovascular Prevention 30 2023 539–550.
56. Rødevand E, Sletvold O, Kvande KT. Bivirkninger av allopurinol. Tidsskrift for den Norske Laegeforening 2004; 124: 2618–2619.
57. Quach C, Galen BT. HLA-B*5801 testing to prevent allopurinol hypersensitivity syndrome a teachable moment. JAMA Internal Medicine 178 2018 1258–1259.
58. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertension Research 2014; 37: 919–925.
59. Hira D, Chisaki Y, Noda S et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology 2015; 96: 90–98.
60. Xie H, Hu N, Pan T, Wu JC, Yu M, Wang DC. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol 2023; 24.
61. Kim LH, Kang SM, Whang J, Kwon KW, Shin SJ. Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection. Antimicrob Agents Chemother 2022; 66.
62. Si X, Huang L, Ding Q et al. Comparison of clinical and economic evaluation between selected generic and original febuxostat tablets in Chinese gout patients with hyperuricemia A real-world multicenter retrospective study. Medicine (United States) 2024; 103: E37081.
63. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. Journal of Rheumatology 2011; 38: 1957–1959.
64. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther 2010; 12.
65. Yu KH, Lai JH, Hsu PN, Chen DY, Chen CJ, Lin HY. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Scand J Rheumatol 2016; 45: 304–311.
66. Maeda K, Tian Y, Fujita T et al. Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. European Journal of Pharmaceutical Sciences 2014; 59: 94–103.
67. Frieden TR, Harold Jaffe DW, Rasmussen SA et al. Sexually Transmitted Diseases Treatment Guidelines, 2015 Morbidity and Mortality Weekly Report CONTENTS (Continued) Centers for Disease Control and Prevention MMWR Editorial and Production Staff (Serials) MMWR Editorial Board. 2015.
68. Guo L, Yang Y, Yang L et al. Comparative study of the effects of baicalin and probenecid on microRNA expression profiles in porcine aortic vascular endothelial cells infected by Glaesserella parasuis. BMC Vet Res 2025; 21: 237.
69. Bergeron HC, Crabtree J, Nagy T, Martin DE, Tripp RA. Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice. Viruses 2024; 16.
70. Murray J, Martin DE, Hosking S, Orr-Burks N, Hogan RJ, Tripp RA. Probenecid Inhibits Influenza A(H5N1) and A(H7N9) Viruses In Vitro and in Mice. Viruses 2024; 16.
71. Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; Clinical experience in high-prevalence population. Journal of Rheumatology 2013; 40: 872–876.
72. Boger WP, Strickland SC. Probenecid (benemid): Its Uses and Side-Effects in 2,502 Patients. AMA Arch Intern Med 1955; 95: 83–92.
73. Padda IS, Bhatt R, Patel P, Parmar M. Pegloticase. 2025.
74. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136–3141.
75. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. Journal of Rheumatology 2000; 27: 1501–1505.
76. Hazard A, Bourrion B, Dechaine F, Fournier L, François M. Lack of evidence for allopurinol for the prevention of a first gout attack in asymptomatic hyperuricemia: a systematic review. European Journal of Clinical Pharmacology 76 2020 897–899.
77. Zhang WZ. Why does hyperuricemia not necessarily induce gout? Biomolecules 11 2021 1–11.
78. Cabău G, Crișan TO, Klück V, Popp RA, Joosten LAB. Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia. Immunological Reviews 294 2020 92–105.
79. Hsu WL, Li SY, Liu JS et al. High uric acid ameliorates indoxyl sulfate-induced endothelial dysfunction and is associated with lower mortality among hemodialysis patients. Toxins (Basel) 2017; 9.
80. Luo Y, Song Q, Li J et al. Effects of uric acid-lowering therapy (ULT) on renal outcomes in CKD patients with asymptomatic hyperuricemia: a systematic review and meta-analysis. BMC Nephrol 2024; 25.
81. Yao X, Cai X, Zhang S et al. Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes. Sci Rep 2025; 15: 4460.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Michał Szczepański, Natalia Dzieszko, Maciej Borowski, Weronika Kalinowska, Paulina Sara Kulasza, Anna Ewelina Francuziak, Piotr Mikołaj Dembicki, Kinga Kozłowska, Tomasz Karol Książek, Aleksandra Szeliga
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 269
Number of citations: 0
